Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05400746
Other study ID # VAC085
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date November 2, 2022
Est. completion date May 30, 2023

Study information

Verified date June 2022
Source University of Oxford
Contact Volunteer Recruitment Co-ordinator Volunteer Recruitment Co-ordi
Phone 01865 611424
Email vaccinetrials@ndm.ox.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living in the UK


Description:

Volunteers will be recruited into one of three groups (n=8-10 per group) at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford over approximately 12 months. All volunteers will receive three dose of Pfs48/45 in 50 µg Matrix-M, administered intramuscularly and given four weeks apart. Enrolment will be staggered with clinical and safety reviews, follow-up visits and monitoring via a diary card.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 30, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy adult aged 18 to 45 years. - Able and willing (in the Investigator's opinion) to comply with all study requirements. - Willing to allow the Investigators to discuss the volunteer's medical history with their GP. - Volunteers with the potential to become pregnant only: must practice continuous effective contraception for the duration of the study (see section 10.10). - Agreement to refrain from blood donation for the duration of the study. - Able and willing to provide written informed consent to participate in the trial Exclusion Criteria: - History of clinical malaria (any species). - Travel to a clearly malaria endemic locality during the study period or within the preceding six months. - Use of immunoglobulins or blood products (e.g., blood transfusion) in the last three months. - Receipt of any vaccine in the 30 days preceding enrolment, or planned receipt of any other vaccine within 30 days following each study vaccination, with the exception of COVID-19 vaccines, which should not be received between 14 days before to 7 days after any study vaccination. - Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period. - Concurrent involvement in another clinical trial or planned involvement during the study period. - Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data, as assessed by the Investigator. - Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). - History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. - Any history of anaphylaxis in reaction to vaccinations. - Pregnancy, lactation or intention to become pregnant during the study. - History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). - History of serious psychiatric condition that may affect participation in the study. - Any other serious chronic illness requiring hospital specialist supervision. - Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 25 standard UK units every week. - Suspected or known injecting drug abuse in the 5 years preceding enrolment. - Hepatitis B surface antigen (HBsAg) detected in serum. - Seropositive for hepatitis C virus (antibodies to HCV) at screening (unless volunteer has taken part in a prior hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV ribonucleic acid (RNA) PCR at screening for this study). - Volunteers unable to be closely followed for social, geographic or psychological reasons. - Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination. In the event of abnormal test results, confirmatory repeat tests will be requested. Procedures for identifying laboratory values meeting exclusion criteria are shown in SOP VC027. - Any other significant disease, disorder, or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. - Inability of the study team to contact the volunteer's GP to confirm medical history

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Pfs48/45 in Matrix-M
Three doses of Pfs48/45 in Matrix-M at different doses

Locations

Country Name City State
United Kingdom CCVTM, University of Oxford Oxford

Sponsors (1)

Lead Sponsor Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of solicited local reactogenicity signs and symptoms for 7 days following each vaccination Occurrence of solicited local reactogenicity signs and symptoms for 7 days following each vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results 7 days following each vaccination
Primary To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following each vaccination Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following each vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results 7 days following each vaccination
Primary To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers by assessing the occurrence of unsolicited adverse events (AEs) for 28 days following the vaccination Occurrence of unsolicited adverse events (AEs) for 28 days following the vaccination using e-diaries, clinical review, clinical examination (including observations) and laboratory results 28 days following the vaccination
Primary To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers. assessed through the number of participants with abnormal laboratory test results Occurrence of change from baseline laboratory tests 28 days following vaccination
Primary To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers assessed through the number of participants with serious adverse events Occurrence of serious adverse events and will be presented according to local grading scales Whole duration of the study (8 months following initial trial vaccination)
Primary To assess safety and tolerability of the Pfs48/45 with Matrix-M vaccine at various doses in healthy adult volunteers. Occurrence of AEs of special interest and will be presented according to local grading scales and will be described in detail Whole duration of the study (8 months following initial trial vaccination)
Secondary To assess the humoral immunogenicity of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers as assessed by humoral responses to the Pfs48/45 protein Antibody responses to the Pfs48/45 protein will be assessed through total IgG isotypes and avidity Days 1, 29, 57, 140 and 240
Secondary To assess the cellular immunogenicity of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers as assessed by cellular responses to the Pfs48/45 protein T cell responses to Pfs48/45 will be assessed by ex vivo enzyme-linked immunospot assays (ELISpot) Days 1, 29, 57, 140 and 240
Secondary To assess ex vivo efficacy of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-reducing activity Transmission-reducing activity Days 1, 29, 57, 140 and 240
Secondary To assess ex vivo efficacy of the Pfs48/45 with Matrix-M vaccine, when administered to healthy adult volunteers using direct membrane feeding assays as assessed by transmission-blocking activity Transmission-blocking activity Days 1, 29, 57, 140 and 240
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02527005 - A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients Phase 1